Member access

4-Traders Homepage  >  Shares  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

314
Real-time Quote. Real-time Tradegate - 02/27 08:10:11 am
67.4 EUR   -3.17%
01/12 UCB : Update of transparency notification UCB SA/NV
01/09 DERMIRA : and UCB announce start of Phase 3 program for CIMZIA (cert..
01/07 UCB : Acquisition of own shares
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
02/23/2015 02/24/2015 02/25/2015 02/26/2015 02/27/2015 Date
68.07(c) 67.61(c) 68.56(c) 69.61(c) 67.31 Last
439 623 299 004 300 488 290 355 366 149 Volume
+1.01% -0.68% +1.41% +1.53% -3.30% Change
More quotes
Company
UCB SA is a biopharmaceutical company that engages in the research, development and commercialization of innovative drugs in the fields of central nervous system and immunology disorders.It focuses on the discovery and development of innovative medicines and solutions to transform the lives of... 
Sector
Pharmaceuticals
Calendar
02/27 | 01:00amEarnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 3 343 M
EBIT 2014 435 M
Net income 2014 241 M
Debt 2014 1 561 M
Yield 2014 1,52%
Sales 2015 3 618 M
EBIT 2015 565 M
Net income 2015 330 M
Debt 2015 1 377 M
Yield 2015 1,69%
PER 2014 55,40
PER 2015 38,31
EV / Sales 2014 4,52x
EV / Sales 2015 4,12x
Capitalization 13 540 M
More Financials
Latest news on UCB
02/12 UCB : Patent Issued for Systems for Administering Medication
02/12 UCB : Patent Issued for Syringe Safety Assembly
01/28 UCB : announces US and EU regulatory filings for the investigational antiepilept..
01/12 UCB : Update of transparency notification UCB SA/NV
01/09 DERMIRA : and UCB announce start of Phase 3 program for CIMZIA (certolizumab peg..
01/07 UCB : Acquisition of own shares
2014 UCB : Selects Cegedim Relationship Management Mobile Intelligence Cloud Platform
2014 UCB : "Method for Producing Protein" in Patent Application Approval Process
More news
Sector news Biopharmaceuticals
08:09a ABBVIE : HUMIRA® (Adalimumab) Receives Positive CHMP Opinion to Treat Children a..
07:46a NOVARTIS : shareholders approve all resolutions proposed by Board of Directors
07:29aDJMerck KGaA 4Q 2014 -- Forecast
Plus d'actualités du secteur Biopharmaceuticals


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF